相关实验视频
Updated: May 20, 2025

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
神经退行性疾病中的分子机制和生物标志物:综合性综述
Nisha Ali1, Usman Sayeed2, Syed Monowar Alam Shahid3
1Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, 226026, India.
像阿尔茨海默氏症和帕金森症这样的神经退行性疾病涉及复杂的遗传和环境因素. 这项研究探讨了它们的分子机制和有希望的新诊断生物标志物,以获得更好的治疗.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 生物化学 生物化学
背景情况:
- 神经退行性疾病 (阿尔茨海默氏症,帕金森病,ALS,亨廷顿病) 构成重大全球健康挑战,影响认知,运动和行为功能.
- 疾病病因是遗传倾向 (例如,APOE,HTT突变) 和环境因素的复杂相互作用.
- 目前的治疗方法主要是治疗症状,这凸显了针对潜在疾病机制的治疗方法的需要.
研究的目的:
- 综合研究驱动神经退行性疾病的分子机制.
- 为了研究蛋白质聚合 (甲胺-β,,α-synuclein) 在疾病发病过程中的作用.
- 突出生物标志物发现和成像用于早期诊断和监测的进展.
主要方法:
- 对分子机制的审查,包括粉样β斑块沉积和阿尔茨海默病中的陶蛋白聚合.
- 对帕金森病中α-synuclein错误折叠的分析.
- 检查异常蛋白质聚合在肌缩侧面硬化和亨廷顿病.
主要成果:
- 详细检查神经退行症背后的分子通路.
- 识别关键的蛋白质错折和聚合过程.
- 强调生物标志物的实用性,如CSF Aβ,tau,α-synuclein和NfL,以及PET成像.
结论:
- 了解分子机制对于开发针对神经退行性疾病的向治疗至关重要.
- 生物标志物的进步,包括基于血液的测试和成像,对于早期诊断和跟踪疾病进展至关重要.
- 这项研究加深了对主要神经退行性疾病的病理生理基础的理解.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
相关概念视频
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Overview
Alzheimer's Disease: Treatment
Neural Regulation
Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...